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Abstract: The members of the PhosphoInositide-3 Kinase (PI3K) protein family are well-known
regulators of proliferative signals. By the generation of lipid second messengers, they mediate
the activation of AKT/PKB (AKT) and mammalian Target Of Rapamycin (mTOR) pathways.
Although mutations in the PI3K/AKT/mTOR pathway are highly characterized in cancer,
recent evidence indicates that alterations in the proliferative signals are major drivers of other
diseases such as overgrowth disorders and polycystic kidney disease. In this review, we briefly
summarize the role of the PI3K/AKT/mTOR pathway in cell proliferation by comparing the effect of
alterations in PI3K enzymes in different tissues. In particular, we discuss the most recent findings
on how the same pathway may lead to different biological effects, due to the convergence and
cooperation of different signaling cascades.
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1. Introduction
Tissue proliferation is a tightly regulated process in the organism, from embryonic development
to adult life. Alterations in this process may cause several pathologic conditions, including cancer,
overgrowth syndromes and polycystic kidney disease. One of the main regulators of cell proliferation
is the PhosphoInositide-3 Kinase (PI3K)/AKT/PKB (AKT)/mammalian Target Of Rapamycin (mTOR)
signaling pathway, which is a well-known target of multiple therapeutic strategies [1].
PI3Ks are a family of lipid kinases subdivided in three classes and eight isoforms. Class I PI3Ks act
as dimers for p110α, p110β and p110δ, where the most common regulatory subunit is p85, while p110γ
associates with the p101 and p84/p87 regulatory subunits. PI3Ks play a key role in the transduction of
signals deriving from activated tyrosine kinase receptors (RTKs), G protein-coupled receptors (GPCRs),
and RAt Sarcoma (RAS). The main product of class I PI3Ks is phosphatidylinositol-3,4,5-triphosphate
PI(3,4,5)P3. This second messenger acts as a docking site for proteins that contain a pleckstrin
homology (PH) domain, such as AKT, which is one of the major downstream effectors of PI3K
and activates a series of downstream signaling pathways, including the AKT/mammalian target of
rapamycin pathway (mTOR). Upon PI3K activation, AKT can be phosphorylated by mammalian target
of rapamycin complex 2 (mTORC2) on serine 473 residue or by phosphoinositide-dependent kinase
1 (PDK1) on threonine 308 residue, leading to inhibition of the tuberous sclerosis protein 2 (TSC2),
a well-known tumor suppressor gene. TSC1 and TSC2 form a multi-protein complex which acts as
a GTPase-activating protein (GAP) for the small GTPase Rheb, thus leading to mTORC1 inhibition.
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AKT-dependent activation of mTORC1 results in increased protein synthesis and cell survival by direct
phosphorylation of downstream effectors, such as the ribosomal S6 kinase.
The activity of PI3K can be opposed by several phosphatases, including phosphatase and tensin
homolog (PTEN), which dephosphorylates PI(3,4,5)P3 back to PI(4,5)P2 [1–3].
Differently from class I and class III, class II PI3Ks (PI3K-C2α, PI3K-C2β, PI3K-C2γ) are monomers
that present distinct long N- and C-terminal domains. In contrast to class I, class II PI3Ks are
predominantly involved in the regulation of vesicular trafficking and recognize PI and PI(4)P as
substrates, producing PI(3)P and PI(3,4)P2, respectively [2–4]. A plethora of different receptors
that modulate PI3K-C2α localization and activation has been reported and includes tyrosine kinase
receptors, such as IR, as well as GPCR. Moreover, PI3Ks can bind small GTPases in multiple contexts.
For example, PI3K-C2α is a RAB11 effector producing PI(3)P at the base of the primary cilium in the
renal tissue, both during development and the adult life. The primary cilium is an organelle protruding
from the cells and, in kidneys, acts as a mechanosensor of the fluid flow. Notably, the primary cilium
plays a key role in the signaling pathways of several proteins, such as Polycystins 1 and 2 (PC1/2) [5],
which are involved in the control of the fluid flow and tubular cell proliferation.
The deletion of PI3K-C2α in mice induced cilium elongation and signaling defects in the embryo
and in kidney tubules, with a defect in Sonic Hedgehog (SH) and PC2 signaling, respectively. In the
embryo, the loss of PI3K-C2α is associated with several defects, including no turning, no cardiac
looping and smaller size [6]. In contrast to PI3KCA, the heterozygous loss of PI3K-C2α increased
proliferation and predisposed the subject to cyst development, in genetic models of PC1/2 reduction
or in response to ischemia-/reperfusion-induced renal damage. Indeed, PI3K-C2α modulates the
trafficking of cargo proteins such as PC2 along the primary cilium, thus allowing polycystin-mediated
control of proliferative signals in kidney tubular cells [7].
In this review, we report the recent findings in PI3K/AKT/mTOR pathway alterations, not only
in the well-known context of cancer, but also in other proliferative disorders such as overgrowth
syndrome and polycystic kidney disease.
2. PI3K Somatic Mutations Leading to Cancer and Proliferative Disorders
The hyper-activation of the PI3K/AKT/mTOR pathway results in significant dysregulation of
cellular functions, which in turn leads to a competitive growth advantage.
Somatic mutations and gains or losses in these genes are linked with many different solid and
hematological tumors [8,9]. PIK3CA is frequently mutated in several cancer types, including breast,
colorectal, endometrial, ovarian and skin tumors [10]. The frequency of mutations indicates that
PIK3CA is one of the most highly mutated oncogenes in human cancers. High-throughput mutational
analysis of human tumor samples revealed that PIK3CA is frequently affected by cancer-specific
somatic mutations in the heterozygous state. Tumor-associated PIK3CA mutations increase the intrinsic
lipid kinase activity of PI3K and provide a growth advantage together with invasive abilities [11,12].
These mutations are distributed over the gene sequence but more than 80% of them are located in
three hotspots, E542 and E545 in the helical domain (exon 9) and H1047 in the kinase domain (exon 20).
E542 and E545 are commonly turned into lysine whereas H1047 is frequently changed to arginine.
Both E545K and H1047R can promote oncogenic transformation in vitro [13], while the latter is also
able to induce tumorigenesis in mice [12,14]. According to structural and functional studies, these two
hotspot mutations act in a synergistic but independent way [15,16]. Mutations of the PIK3CA gene are
described in 25%–40% of breast cancers and in 30% of colorectal cancer [17], while PIK3CA mutations
in endometrial cancer are often coincident with PTEN inactivation [18].
Interestingly, hotspot mutations occur also in noninvasive keratinocyte-derived skin lesions,
including epidermal nevi and seborrheic keratosis [19,20]. In contrast, PIK3CA mutations are relatively
rare in malignant melanoma (~3%), despite the critical role of PTEN inactivation in this tumor type [21].
Interestingly, in addition to their well-characterized role in cancer, postzygotic somatic
mutations in PIK3CA have also recently been identified in a spectrum of overgrowth disorders
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including congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies
(CLOVES) syndrome, PIK3CA-related overgrowth spectrum (PROS), Proteus syndrome (PS) and
other AKT-related disorders.
Distinct nodes in the PI3K signaling pathway, from receptor proteins on the cell surface to protein
kinases, are implicated in mosaic overgrowth syndromes. Notably, mutations are almost exclusively
found in tissues of ectodermal and mesodermal origin, with overgrowth frequently affecting adipose,
muscle and skeletal tissue [22]. These disorders are all caused by mutations affecting pathways that,
by regulating cellular growth, are prominently involved in cancer. However, while some of these
phenotypes predispose to malignancies, the majority do not. Generally speaking, cancer originates
from a normal cell that has undergone a tumorigenic transformation as a result of genetic mutations,
which is defined as the tumor-initiating cell. The cell type of origin together with genetic alterations
contribute to the oncogenic phenotype, as has been recently demonstrated in breast cancer [23].
This suggests that the context (both temporal and cellular) in which the mutation occurs determines its
phenotype, conferring heterogeneity to the spectrum of disease burden.
On the other hand, germline loss-of-function mutations of PTEN and TSC1/TSC2 cause PTEN
hamartoma tumor syndrome and tuberous sclerosis complex. In all these conditions, the affected sites
show increased activation of the PI3K and mTOR pathways, together with an increased proliferation
rate of the tissue involved.
PI3K/mTOR-dependent aberrant growth can also affect several tissues, including kidneys,
where it results in cyst formation.
3. The PIK3CA-Related Spectrum of Overgrowth Syndromes
It has been reported that PI3K pathway components are somatically mutated in a spectrum
of congenital or early-childhood-onset human disorders [24,25]. Some of these de novo mutations
are usually somatic, as the corresponding germline mutations would lead to extremely pervasive
developmental disorders, which would result in embryonic lethality [26]. A common feature of
these disorders is the aberrant activation of cellular proliferation pathways and overgrowth, which
have been therefore referred-to as “overgrowth syndromes”. Although each syndrome has a specific
panel of clinical features, some overlapping characteristics can be determined. Similarly, such a
phenotypic overlap was previously recognized for the large group of RAS-related syndromes,
collectively referred-to as “RASopathies”, which are caused by activating mutations affecting RAS
signaling components [27], and mainly occurring in the germline (albeit mosaic RASopathies have
also been identified) [28].
The overgrowth syndromes comprise a wide group of clinically recognizable mutation-driven
congenital malformations [29]. Among these, the PIK3CA-related overgrowth spectrum (PROS)
congenital disorders are caused by a range of mosaic-activating mutations in the PIK3CA gene,
coding for p110α.
The different mutations underlying PROS disorders result in moderate-to-strong constitutive
activation of PIK3CA (Table 1), leading to the increased growth of the affected tissues [30]. The PROS
spectrum is broad, from weak phenotypes to dramatic malformations, reflecting the effect of mutations
during embryogenesis and in progenitor cells [31]. Within PROS, some distinct entities can be
recognized, despite considerable overlap.
Cutaneous defects together with developmental neurological abnormalities are normally present
in macrocephaly-capillary malformation (MCAP) and CLOVES. In addition, several disorders are
associated with connective tissue overgrowth, presumably arising from mutations affecting progenitor
cells committed to a mesenchymal fate. Of note, MCAP can be occasionally caused by germline
PIK3CA mutations [32]. Malignancies are rare in the PROS spectrum [24], even if PIK3CA is the most
common mutated gene in cancer.
Another class of overgrowth diseases, the PTEN hamartoma tumor syndrome (PHTS), is caused
by mutations in the PTEN tumor suppressor gene. In particular, heterozygous inactivating germline
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genetic lesions occur in the PTEN gene and they are responsible for 90% of Cowden syndrome (CS)
cases. CS has a wide clinical spectrum, including skin abnormalities, macrocephaly and predisposition
to multiple cancer types, including breast, colon and thyroid [33]. In segmental overgrowth,
lipomatosis, arteriovenous malformation, and epidermal nevus (SOLAMEN), classic manifestations of
CS are combined with segmental overgrowth, arteriovenous and lymphatic malformations, lipomas,
and epidermal nevi. SOLAMEN symptoms are related to mosaic loss of the healthy PTEN allele in
patients carrying a germline PTEN mutation [34]. This phenomenon, known as type 2 mosaicism,
has been extensively documented for other genetic disorders. Interestingly, the patients do not develop
malignancies in the tissues affected by PTEN loss.
In 2011, Lindhurst et al. reported a mosaic-activating AKT1 mutation that causes Proteus
syndrome (PS) [35], which is associated with prominent skin and vascular malformations. In addition,
the other AKT family members, AKT2 and AKT3, have also been implicated in overgrowth
syndromes [32,36].
While most of the previous studies have been focused on germline mutations, thanks to
deep-sequencing technologies, there is increased evidence that somatic mutations also are related to
non-cancer phenotypes. However, there are no available mouse models that fully recapitulate the wide
spectrum of phenotypes which characterize PI3KCA-related overgrowth syndromes.
Table 1. PIK3CA-related overgrowth spectrum (PROS). PIK3CA predicted mutations and associated
clinical overgrowth disorders (for a comprehensive study please see Keppler-Noreuil 2015) [31]).
Clinical PROS Disorder Mutation (Gene Domain) References
Megalencephaly-capillary malformation
syndrome (MCAP)
E81K, R88Q (p85 BD)
G364R, E365K, C378Y, E452K, E453K, E453del (C2)
E542K, E545K (Helical)
E726K
G914R, Y1021C, T1025A, A1035V (Kinase)
H1047L, H1047R, M1043I, H1047Y, G1049S (Kinase)
[32]
Congenital lipomatous overgrowth, vascular
malformations, linear keratinocytic epidermal
nevi, and skeletal or spinal anomalies
(CLOVES) syndrome
C420R
E542K, E545K (Helical)
H1047L, H1047R (Kinase)
[24,37,38]
Fibroadipose overgrowth
(FAO)/Hemihyperplasia multiple
lipomatosis (HHML)
E542K, E545K (Helical)
H1047L, H1047R (Kinase) [39,40]
Macrodactyly
R115P
E542K, E545K (Helical)
H1047L, H1047R (Kinase)
[41]
Hemimegalencephaly E542K, E545K (Helical) [42]
Muscle hemihyperplasia E542K, E545K (Helical)H1047L, H1047R, L1067fs (Kinase) [41]
Facial infiltrating lipomatosis
E452K, E453K, E453del (C2)
E542K, E545K (Helical)
H1047L, H1047R (Kinase)
[43]
Epidermal nevi E542K, E545K (Helical)H1047L, H1047R (Kinase) [19]
Seborrheic keratoses E542K, E545K (Helical)H1047L, H1047R (Kinase) [19]
Benign lichenoid keratoses E542K, E545K (Helical) [19]
4. PI3Ks Inhibitors as a Therapeutic Challenge in Overgrowth Syndromes
Due to the extensiveness of vascular malformations and tissue overgrowth, PI3K-related
syndromes pose a therapeutic challenge. Sclerotherapy or surgery might improve symptoms or
ameliorate patients’ appearance, but complete remission is seldom seen. As genetic alterations in
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PI3K/AKT/mTOR signaling have been recognized as pivotal cancer drivers, considerable efforts have
been employed to generate a plethora of inhibitors for such pathway components. Several of these
compounds are in clinical trials for cancer and may be reasonably re-purposed as targeted therapies
for overgrowth conditions [44]. Recently, an association between somatic mutations in PIK3CA and
sporadic venous malformations in mouse models have been demonstrated [45,46]. Both studies
highlighted the efficacy of selective PI3Kα and mTOR inhibitors to reduce the size and proliferation of
these malformations. Even if there are not any clinical trials to evaluate PI3K p110α inhibitors in PROS,
pre-clinical studies in both PROS and cancers bearing PIK3CA mutations have yielded promising
results [30].
Several AKT inhibitors are now in clinical trials for cancer. Notably, a phase I trial of
ARQ 092, a pan-AKT inhibitor, is underway in children and adults with Proteus syndrome
(ClinicalTrials.gov: NCT02594215). Allosteric inhibitors of mTOR, including sirolimus (rapamycin),
everolimus, ridaforolimus, temsirolimus, are licensed therapies for a range of conditions [47]. Notably,
off-label applications of mTOR inhibitors might be successfully exploited also in non-cancer diseases.
Very recently, rapamycin has been suggested as a systemic therapy to reduce vascular malformations
in patients [48,49], including those carrying PTEN mutations [50,51]. A clinical trial investigating
sirolimus in PROS (ClincalTrials.gov: NCT02428296) is currently underway, with expected completion
in 2017. Of greatest relevance to PI3K/AKT-related disorders are dual PI3K-mTOR inhibitors, which are
currently in phase I trial for cancer [52].
Of note, patients with somatic activation of the PI3K/AKT pathway may need life-long therapy
with the inhibitor. This raises concern not only for the more common adverse effects of these inhibitors,
but also for unknown effects that cannot be revealed by short-term evaluation in clinical trials, this being
a critical challenge which already emerged for RAS-related syndromes. Unfortunately, data from
preclinical studies in a disease model are scarce. Recently, Kinross et al. systemically overexpressed the
H1047R mutation of PIK3CA, leading to increased body weight with enlarged organs due to increased
cell number [53]. In addition, Hare et al. overexpressed the PIK3CA H1047R mutation specifically in
endothelial cells, leading to extensive vascular remodeling and embryonic lethality [54].
5. PI3Ks as a Master Controller of Proliferation in the Kidney and in Polycystic Kidney Disease
Besides cancer [1] and overgrowth syndromes [44], alterations in the PI3K/AKT/mTOR pathway
are major drivers of abnormal proliferation. In the kidney, the hyper-proliferation of tubular cells
induces renal cyst formation, which can be considered a sort of overgrowth syndrome and is typical of
polycystic kidney disease (PKD). In this context, the increased proliferation can be caused by opposite
genetic lesions occurring in PI3Ks: on one side, hyper-activation of the AKT-dependent class I PI3KCA
signaling pathway, on the other side, loss of class II PI3K-C2α.
In PKD, it is well described that alterations of several components of the PI3K/AKT/mTOR
pathway, already found in cancer, are implicated in the hyper-proliferation of renal tubular cells,
such as TSC. TSC is a well-known tumor suppressor, which is negatively regulated by AKT and
acts as a GTPase Activating Protein (GAP) for the small GTPase Rheb, thus leading to mTORC1
inhibition. TSC1 and TSC2 genes are mutated in a genetic disorder called tuberous sclerosis complex
(TSC). TSC causes the development of hamartomas, which can arise in multiple organs, including
brain, kidney, skin and liver. Humans and mice with loss of either TSC1 or TSC2 are prone to
developing renal problems including cysts, which usually do not interfere with kidney function [55].
However, in a small subset of patients with loss of TSC and who were affected by severe infantile
polycystic kidney disease, cysts led to renal failure [56]. It was reported that conditional knockout
of TSC1 in renal tubular cells resulted in PKD [57]. Both the hyper-activation of class I PI3KCA
and the inhibition of TSC result in the mTOR-mediated increase in cell proliferation. Besides its
AKT-mediated inhibition, TSC can be activated by polycystins. Polycistin-1 acts as a mechanosensor
of the fluid flux and activates the calcium channel Polycistin-2. These two transmembrane proteins
are encoded by PKD1 or PKD2 genes, which are mutated in autosomal-dominant polycystic kidney
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disease (ADPKD), a genetic disorder characterized by uncontrolled proliferation of renal cells with
the consequent formation of cysts and loss of renal function [58,59]. The anti-proliferative signal of
polycystins due to mTORC1 inhibition is mediated by TSC1 and TSC2 genes. Mice with concomitant
loss of TSC and PC1 revealed that cyst development is closely correlated with elevated mTORC1
activity, leading to hypertrophy and increased proliferation of the renal tubular cells [60]. In cells,
the coexistence of mutation and loss of TSC alleles presented an alteration in the localization of PC1 on
the plasma membrane [57]. Re-expression of PC1 in the TSC1-mutant kidneys corrects the phenotype.
On the other hand, mTORC1 acts in a negative feedback loop to downregulate PC1 expression levels.
Consistently, the inhibition of mTOR increases the expression levels of polycystins and slows cyst
expansion [60,61].
Conversely, mTOR activation is also triggered by the loss of a class II PI3K-C2α, which is important
for the correct transport of Polycystins along the primary cilium. Polycystins exert their function
only when properly localized on this organelle [62]. The localization of PC2, in turn, is required for a
correct transduction of the anti-proliferative signal, inhibiting intracellular pathways, including the
mTOR and mitogen-activated protein kinase (MAPK) pathways, eventually avoiding cystogenesis [63].
The transport of PC2 along the primary cilium is mediated by the small guanosine triphosphatase
(GTPase) RAB8, which in turn is regulated by RAB11. It was demonstrated that PI3K-C2α acts
at the pericentriolar recycling endosomal compartment (PRE) at the base of the primary cilium
where it produces PI(3)P and promotes RAB11 activation upstream of RAB8 [6,7,64]. The inhibition
of PI3K-C2α decreases the number of PC2-positive cilia, resulting in increased mTOR and MAPK
signaling. Accordingly, the expression of a constitutive active form of RAB8 (RAB8Q67L) is able
to restore these defects. Indeed, the concomitant heterozygous loss of PI3K-C2α and PC1 or PC2
correlates with a higher number of cysts in proximal and distant tubules. These data indicate that
PI3K-C2α activates the RAB11/RAB8 cascade, regulating the transport of cargo proteins, such as
polycystins, along the primary cilium, thus preventing cyst formation [7]. These data point out that
uncontrolled proliferation is due to the hyper-activation of class I PI3KCA or loss of class II PI3K-C2α.
For class I PI3K, the proliferation signal is induced by the PI(3,4,5)P3-mediated activation of AKT,
which in turn enhances mTOR activity. On the contrary, for class II PI3K, cell proliferation seems to be
triggered by polycystin-mediated inhibition of mTOR. The apparent contradiction of these different
PI3Ks could be explained by the lack of the AKT-activating PI(3,4,5)P3 production by class II PI3K.
Consistently, PI3K-C2β knockout enhances insulin/AKT signaling in metabolic tissues, probably due
to a compensatory enhancement of class I PI3K activation, which produces PI(3,4,5)P3 and activates
AKT [65].
In the prevention of cyst formation, negative regulators of PI3Ks, including PTEN, are implicated.
PTEN loss per se is not sufficient to induce cyst development [66]; conversely, the concomitant loss of
PTEN and other tumor suppressor genes, such as Von Hippel-Lindau (VHL) and TSC, was implicated
in cyst formation. VHL syndrome is a familiar cancer which predisposes to a variety of malignant and
benign tumors. In some patients, kidney cysts are precursor lesions for clear cell renal cell carcinoma
(ccRCC), one the most common malignant kidney tumors. Cysts in human VHL patients, but not VHL
mutant cells, display hyper-activation of the PI3K/AKT/mTOR signaling pathways, indicating that
PI3K mutations may be an early event in the transformation process. Double-knockout mice for PTEN
and VHL showed enlarged and heavier kidneys due to multiple cysts, characterized by a lack of
primary cilium, increased proliferation and activated PI3K signaling [67,68]. Similarly, it was reported
that mice lacking PTEN and TSC1 develop severe PKD [66]. This suggests that concomitant mutations
are needed to induce cyst development in a cancer-prone background.
A recent study identified a four-gene signature as a prognostic value for ccRCC, including PTEN,
PIK3C2A, ITPA and BCL3 [69]. Moreover, low expression of PTEN and PIK3C2A was correlated with
high risk and poor prognosis [69].
By now, the only available therapies for ADPKD are supportive treatments, such as regulation
of blood pressure, and dialysis or kidney transplantation are often required. Given the concomitant
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alterations of pathways other than mTOR, the efficiency of molecular target therapies, such as sorafenib
and temsirolimus, is limited to 10%–40%. Preclinical trials based on mTOR inhibition (mTOR-I) by
either the immunosuppressant sirolimus (SIR) [61,70] or everolimus (EVER) [71] demonstrated that the
sirolimus injection led to increased kidney size, cyst density and tubular cell proliferation. However,
in clinical trials only negligible effects on cyst growth and preservation of renal function were observed,
due to the development of resistance [72,73]. In particular, it was demonstrated that sirolimus treatment
may restore a cell’s ability to activate AKT, suggesting that patients with TSC show a high risk of
malignant tumor development due to long-term treatment [74]. Up to now, the most important
supportive treatment for ADPKD is the regulation of blood pressure. A clinical trial for tolvaptan,
a vasopressin 2 receptor (V2R) antagonist, is still under Food and Drug Administration (FDA) approval,
due to the request for further information about side effects and selection of patient cohorts who may
benefit from treatment (clinicaltrials.gov). As V2R is a GPCR-coupled receptor whose downstream
pathway is mediated by PI3Ks, we can speculate that the targeting of PI3K itself, but not mTOR,
could be beneficial in the treatment of ADPKD.
6. Conclusions
PI3K/AKT/mTOR is frequently deregulated in several proliferative disorders, from cancer to
overgrowth syndromes and polycystic kidney disease. Despite similar mutations, patients develop
a plethora of different disorders. For example, PIK3CA mutations associated with overgrowth
syndromes are often similar to those observed in cancer, but these patients do not seem to be
predisposed to cancer. Similarly, loss of tumor suppressor genes such as TSC1 and TSC2 is not
always accompanied by the development of renal cysts and overgrowth. This suggests that the role of
mutations in disease is determined by the context in which they occur. Clinical variability may depend
on the timing of the mutation during embryogenesis, the type of tissue affected and concomitant
secondary lesions. On the other hand, the common molecular basis of these disorders is associated
with significant clinical overlap. This will eventually help to apply the therapeutic strategies used for
well-studied pathologies, such as cancer, to emerging clinically relevant diseases, such as overgrowth
syndrome and polycystic kidney disease. Conversely, patients with ADPKD did not benefit from
rapalogs treatment, indicating that mTOR-mediated signaling is not the only pathway involved in cyst
formation. These clinical failures imply that a novel therapeutic option could be based on the single or
combined targeting of PI3K pathway components.
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